Investing.com – Pfizer Q3 Financial Report

Pfizer (NYSE: PFE) reported a third-quarter EPS of $1.06, exceeding the analyst estimate of $0.62 by $0.44. Revenue for the quarter was $17.7B, surpassing the consensus estimate of $14.92B.

Guidance

• FY 2024 EPS: $2.75-$2.95 (analyst consensus: $2.65)
• FY 2024 Revenue: $61.00B-$64.00B (analyst consensus: $61.20B)

Pfizer's stock price closed at $28.86, with a decline of -5.84% over the last 3 months and -5.53% over the last 12 months.

In the last 90 days, Pfizer had 14 positive EPS revisions and 2 negative EPS revisions. Pfizer's Financial Health score is rated as fair performance according to InvestingPro.

For more details, check out Pfizer's recent earnings performance and financials.

Stay informed about upcoming earnings reports by visiting Investing.com's earnings calendar.